Literature DB >> 15518792

Efficacy of IgM anti-blood type antibody monitoring by enzyme-linked immunosorbent assay after renal transplantation across the blood barrier: high-dose immunoglobulin administration blocks IgM rather than IgG anti-blood type antibodies.

H Ishida1, K Tanabe, M Furusawa, T Isizuka, T Tokumoto, H Shimmura, T Shimizu, N Miyamoto, T Hayashi, H Toma.   

Abstract

We used an enzyme linked immunosorbent assay (ELISA) to investigate the presence of subtypes of anti-blood-type antibodies in patients with biopsy-proven humoral rejection after ABO-incompatible renal transplantation. High agglutinin IgG and IgM anti-blood type antibodies from 12 ABO-incompatible recipients with vascular rejection were separately assessed using an ELISA. Patients who exhibited excellent renal function despite high agglutinin titers of anti-blood-type antibodies(n = 8) were also examined. All 12 rejection patients exhibited highly elevated titers of IgG and IgM, while the eight stable patients exhibited only slightly elevated IgG titers, but not IgM. IgG and IgM titers did not change after plasmapheresis and steroid pulse therapy, whereas IVIg treatment significantly blocked both IgG and IgM, with IgM being blocked to a larger extent than IgG. Blocking of IgM seems to play an important role in improving ABO-incompatible grafts.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15518792     DOI: 10.1016/j.transproceed.2004.08.082

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  2 in total

1.  ABO-incompatible pediatric kidney transplantation without antibody removal.

Authors:  Takeshi Kawamura; Yuko Hamasaki; Yusuke Takahashi; Junya Hashimoto; Mai Kubota; Masaki Muramatu; Yoshihiro Itabashi; Yoji Hyodo; Yasushi Ohashi; Atushi Aikawa; Ken Sakai; Seiichiro Shishido
Journal:  Pediatr Nephrol       Date:  2019-10-31       Impact factor: 3.714

2.  Late antibody-mediated rejection after ABO-incompatible kidney transplantation during Gram-negative sepsis.

Authors:  Annelies de Weerd; Alieke Vonk; Hans van der Hoek; Marian van Groningen; Willem Weimar; Michiel Betjes; Madelon van Agteren
Journal:  BMC Nephrol       Date:  2014-02-12       Impact factor: 2.388

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.